Table 3. Adverse effects and toxicity assessed by the NCI Common Terminology Criteria for Adverse Events version 5.0 for patients with advanced HCC treated with IO, TKI, and BSC.

Adverse effect	IO, n=27	TKI, n=6	BSC, n=25	P value
Nausea (%)				0.135
0	17 (63.0)	4 (66.7)	12 (48.0)
1	3 (11.1)	1 (16.7)	0 (0.0)
2	7 (25.9)	1 (16.7)	13 (52.0)
Fatigue (%)				0.312
0	5 (18.5)	1 (16.7)	1 (4.0)
1	17 (63.0)	5 (83.3)	16 (64.0)
2	4 (14.8)	0 (0.0)	8 (32.0)
3	1 (3.7)	0 (0.0)	0 (0.0)
Diarrhea (%)				0.238
0	21 (77.8)	5 (83.3)	20 (80.0)
1	5 (18.5)	0 (0.0)	1 (4.0)
2	1 (3.7)	1 (16.7)	4 (16.0)
Hand-foot syndrome (%)				–
0	27 (100.0)	2 (33.3)	25 (100.0)
1	0 (0.0)	0 (0.0)	0 (0.0)
2	0 (0.0)	4 (66.7)	0 (0.0)
Rash excluding hand-foot syndrome (%)				0.008
0	17 (63.0)	3 (50.0)	25 (100.0)
1	5 (18.5)	1 (16.7)	0 (0.0)
2	5 (18.5)	2 (33.3)	0 (0.0)
Immune mediated reactions (%)				0.283
0	19 (70.4)	5 (83.3)	25 (100.0)
1	2 (7.4)	0 (0.0)	0 (0.0)
2	4 (14.8)	1 (16.7)	0 (0.0)
3	1 (3.7)	0 (0.0)	0 (0.0)
4	1 (3.7)	0 (0.0)	0 (0.0)
Cytopenias (%)				0.052
0	25 (92.6)	5 (83.3)	24 (96.0)
1	2 (7.4)	0 (0.0)	1 (4.0)
2	0 (0.0)	1 (16.7)	0 (0.0)
Elevated blood pressure (%)	0 (0.0)	1 (16.7)	1 (4.0)	0.126

HCC, hepatocellular carcinoma; IO, immunotherapy; TKI, tyrosine kinase inhibitor; BSC, best supportive care.